MedTrace Logo

For Patients With Early-Stage Non-Small Cell Lung Cancer or Lung Oligo-metastatic Tumor, Applying Pulsed Electric Field Energy Through Percutaneous Approach To Ablate the Tumor and Evaluate the Safety and Initial Efficacy.

NCT07799194 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-09-03

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the performances of a percutaneous Pulsed Electrical Field (PEF) ablation to treat patients with primary early-stage lung cancer (NSCLC) or lung oligometastatic Tumors who are unresectable or refusal surgery/Radiotherapy.

The main questions the study aims to answer are:

The safety and technical feasibility of the PEF ablation. The preliminary efficacy of the PEF ablation for target lesion in lung

Patients who meet the inclusion/exclusion criteria will be given percutaneous PEF ablation to the target lesions under general anesthesia. Then follow-up to 12 months to monitor any progression by about 3 months interval.

Target Subject： Patients with early-stage primary non-small cell lung cancer(NSCLC) or pulmonary oligometastatic tumors who are not surgical resectable or unsuitable for surgery/radiotherapy

Conditions

  • Lung Cancer (NSCLC)

Interventions

DEVICE

Pulsed Electric Field Ablation

Application of Pulsed Electric Field energy to ablate the lung tumor through percutaneous approach.

Sponsors & Collaborators

  • Energenx Medical LTD.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-12-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07799194 on ClinicalTrials.gov